Leroy M J, Cedrin I, Breuiller M, Giovagrandi Y, Ferre F
INSERM U-166, Maternité Baudelocque, Paris, France.
Biochem Pharmacol. 1989 Jan 1;38(1):9-15. doi: 10.1016/0006-2952(89)90142-1.
The present study was carried out to determine the ability of various pharmacological agents to selectively inhibit each cytosolic form of phosphodiesterase isolated from the longitudinal layer of human myometria near term. Among the drugs tested, zaprinast specifically inhibits the first form of PDE which hydrolyses both substrates (cAMP and cGMP) and is stimulated by the Ca2+-calmodulin complex. A second form of PDE specific for cAMP hydrolysis and Ca2+-calmodulin insensitive is only present during pregnancy. Rolipram is the most potent and selective inhibitor of this second form. It is also the most efficient compound to inhibit in vitro the spontaneous contractions of near term myometria. The double effect of rolipram suggests an important role of the second form of PDE in the mechanisms of contractility during the pregnancy. In addition rolipram or other derivatives might be of a therapeutic interest in the prevention of prematurity in so far as they are devoid of undesirable maternal and fetal side effects.
本研究旨在确定各种药理剂选择性抑制从接近足月的人子宫肌层纵行层分离出的每种胞质形式磷酸二酯酶的能力。在所测试的药物中,扎普司特特异性抑制第一种形式的磷酸二酯酶,该酶可水解两种底物(环磷酸腺苷和环磷酸鸟苷)并受Ca2 + -钙调蛋白复合物刺激。第二种形式的磷酸二酯酶对环磷酸腺苷水解具有特异性且对Ca2 + -钙调蛋白不敏感,仅在怀孕期间存在。咯利普兰是这种第二种形式最有效和选择性的抑制剂。它也是体外抑制接近足月子宫肌层自发收缩最有效的化合物。咯利普兰的双重作用表明第二种形式的磷酸二酯酶在怀孕期间的收缩机制中起重要作用。此外,咯利普兰或其他衍生物可能在预防早产方面具有治疗意义,因为它们没有不良的母体和胎儿副作用。